Abstract 109P
Background
With 18F-FDG PET/CT, tumor uptake intensity and textural features have been associated with outcome in several types of cancer. This study was to evaluate the prognostic value of pretreatment 18F-FDG PET/CT textural parameters in patients with primary metastatic colorectal cancer (CRC).
Methods
All patients (n = 104) who had had a pretreatment image of 18F-FDG PET/CT at our Hospital from January 2009 to December 2015 were included. Volumes of interest (VOIs) were drawn freehand around the tumor, and texture analysis was conducted on both CT and PET images within the same VOIs. A total of 35 features were extracted and analyzed. Univariate and multivariate analyses (logistic regression) were conducted to assess the prognostic value of textural parameters. Moreover, radiomics score (rad-score) was constructed using logistic regression. A multivariate logistic regression model was then used to establish a nomogram including the rad-score and other clinicopathological features.
Results
The results of univariate analysis showed that 18 textural parameters such as skewness and kurtosis were significantly associated with survival. In multivariate model, 17 textural parameters were shown to be able to predict PFS, including skewness (HR 2.777, p < 0.001), kurtosis (HR 0.441, p < 0.001), entropy (HR 1.704, p = 0.014), homogeneity (HR 0.548, p = 0.006), SRE (HR 1.853, p = 0.005), LRE (HR, p = 0.005), HGRE (HR 1.616, p = 0.036), LZE (HR 0.597, p = 0.018), LGZE (HR 0.439, p < 0.001) and HGZE (HR 2.085, p = 0.001). In addition, 8 textural parameters such as skewness (HR 4.475, p < 0.001), kurtosis (HR 0.377, p < 0.001), SRHGE (HR 2.062, p = 0.005) and LRLGE (HR 0.475, p = 0.003), were revealed to be independent predictors of OS among our population.
Conclusions
The texture analysis of the baseline 18F-FDG PET/CT appears to be a potential tool to predict outcomes of patients with primary metastatic CRC. However, prospective studies with a large population are needed to confirm the present findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract